Skip to main content

Cytomx Therapeutics

CytomX Therapeutics Inc is an American clinical-stage oncology biopharmaceutical enterprise specializing in the discovery, development, and commercialization of novel antibody therapeutics designed to treat cancer, prominently featuring its proprietary Probody technology platform (conditionally activated antibody therapeutics engineered to remain inert in healthy tissue and become active specifically within the tumor microenvironment). The company conducts advanced clinical trials evaluating targeted Probody drug conjugates (PDCs) and T-cell engaging therapies designed to expand the therapeutic window of oncology drugs. Its core business operations encompass biopharmaceutical research, Probody platform engineering, clinical trial execution, and collaborative biopharmaceutical licensing. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its research activities through collaborative R&D licensing agreements, milestone payments, and public equity offerings. CytomX Therapeutics holds a pioneering global market position in conditionally activated antibody therapeutics and Probody technology. The company is headquartered in South San Francisco, California, United States, and its common stock trades on the Nasdaq Global Market under the ticker CTMX.

3 of the funds FundTelligence covers report a position in Cytomx Therapeutics.

Legal name
Cytomx Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
3

Funds holding Cytomx Therapeutics

Loading...